European Journal of Cancer

Volume 30A, 1994

List of Contents and Author Index

PERGAMON

European Journal of Cancer

Editor in Chief:

MICHAEL PECKHAM
Director of Research and Development
Department of Health

Editors:

MATTI AAPRO, *Centre Anticancéreux, Clinique de Genolier, 1261 Genolier, Switzerland*

PETER BOYLE, *Division of Epidemiology and Biostatistics, Istituto Europeo di Oncologia, Milan, Italy*

IAN HART, *Imperial Cancer Research Fund Laboratories, Lincoln's Inn Fields, London WC2A 3PX, U.K.*

EMMANUEL VAN DER SCHUEREN, *University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium*

UMBERTO VERONESI, *Istituto Europeo di Oncologia, via Ripamonti 435, 20141 Milan, Italy*

European Journal of Cancer Part B: Oral Oncology
CRISPIAN SCULLY, *Eastman Dental Institute for Oral Healthcare Sciences, 256 Grays Inn Road, London WC1X 8LD, U.K.*

Education and Training in Oncology Section: **Alberto Costa,** *European School of Oncology, Milan, Italy*

Editorial Office: **European Journal of Cancer,** *British Postgraduate Medical Federation, 33 Millman Street, London WC1N 3EJ, U.K.*
Telephone 44-71-430-0100 Fax 44-71-430-0072

Senior Advisors

Kari Alitalo, Harry Bartelink, Henri Bismuth, Walter Bodmer, Gianni Bonadonna, Piet Borst, Frans Cleton, Derek Crowther, Louis Denis, Jean-Pierre Gerard, Jack Hardcastle, Jean-Claude Horiot, Gordon McVie, Jacques Ninane, Jens Overgaard, Thierry Philip, Herbert Pinedo, Manfred Rajewsky, Bruno Salvadori, Harald Stein

Consulting Editors:

G Adams, *UK*
F Alexander, *UK*
J P Armand, *France*
D Ash, *UK*
C Balch, *USA*
A Balmain, *UK*
P Bannasch, *Germany*
M Baum, *UK*
M Beato, *Germany*
M Boiron, *France*
T Boon, *Belgium*
A Breit, *Germany*
M H Bronchud, *Spain*
M M Burger, *Switzerland*
F Cavalli, *Switzerland*
P A Cerutti, *Switzerland*
J Costa, *USA*
L Crawford, *UK*
A Cull, *UK*
J Cuzick, *UK*
F Cuzin, *France*
O Dahl, *Norway*
N E Day, *UK*
F Demard, *Italy*
T M Dexter, *UK*
H Diggleman, *Switzerland*
R S Dondelinger, *Belgium*
J van Dongen, *The Netherlands*
F Eschwege, *France*
I S Fentiman, *UK*
R Flamant, *France*
S Foden, *UK*
S Franceschi, *Italy*
Z Fuks, *USA*
G Gabbiani, *Switzerland*
D Gadian, *UK*
C G Gahmberg, *Finland*
G Gahrton, *Sweden*
B Geiger, *Israel*
G P Georgiev, *Russia*
P Ghadirian, *Canada*
R Greiner, *Switzerland*
K Griffiths, *UK*
B Groner, *Switzerland*
B Gusterson, *UK*
A Hagemeijer, *The Netherlands*
M Hakama, *Finland*
H H Hansen, *Denmark*
A Harris, *UK*
H zur Hausen, *Germany*
C-H Heldin, *Sweden*
C Henderson, *USA*
T Hercend, *France*
A Horwich, *UK*
C Hsieh, *USA*
C Huber, *Germany*
M D'Incalci, *Italy*
V C Jordan, *USA*
H Jurgens, *Germany*
K Katsouyanni, *Greece*
S B Kaye, *UK*
G Klein, *Sweden*
S von Kleist, *Germany*
A Knudson, *USA*
A van der Kogel, *The Netherlands*
D Kogelnik, *Austria*
H Koprowski, *USA*
S Lamberts, *The Netherlands*
A Langlands, *Australia*
H Lehrach, *UK*
F Levi, *Switzerland*
D Louvard, *France*
J P Mach, *Switzerland*
P Maguire, *UK*
J Maher, *UK*
C Mahler, *Belgium*
C Marshall, *UK*
V Marshall, *Australia*
J Martin-Moreno, *Spain*
E Marubini, *Italy*
R Mertelsmann, *Germany*
D Metcalf, *Australia*
U Metzger, *Switzerland*
S Meuer, *Germany*
J Minna, *USA*
I Mittra, *India*
S Monfardini, *Italy*
H T Mouridsen, *Denmark*
C S Muir, *UK*
E Negri, *Italy*
F Oesch, *Germany*
A van Oosterom, *Belgium*
A Peracchia, *Italy*
L Peters, *USA*
J Pritchard, *UK*
D Raghavan, *USA*
G Riethmuller, *Germany*
F Rilke, *Italy*
E Rozengurt, *UK*
R Saracci, *France*
P Scalliet, *Belgium*
P Schlag, *Germany*
G Schwartsmann, *Brazil*
H J Senn, *Switzerland*
M Slevin, *UK*
J F Smyth, *UK*
D Sommelet-Olive, *France*
E J Stanbridge, *USA*
G Steel, *UK*
R Stuart-Harris, *Australia*
R Sutherland, *Australia*
H Svensson, *Austria*
R Sylvester, *Belgium*
M Tattersall, *Australia*
P Tiollais, *France*
D Trichopoulos, *USA*
I Turesson, *Sweden*
J M Vasiliev, *Russia*
L J Vatten, *Norway*
C La Vecchia, *Italy*
V Ventafridda, *Italy*
P A Voûte, *The Netherlands*
A Vritsios, *Greece*
H R Withers, *USA*
P Workman, *UK*
M Yaniv, *France*
D Zaridze, *USSR*
W Zatonski, *Poland*
R Zittoun, *France*

Society and News Correspondents

EORTC	F Meunier	**FECS**	J Smyth
ESO	V Majstorovic	**ESTRO**	J W H Leer
ESMO	H Cortes-Funes	**EACR**	M R Price
ESSO	W Mattheiem	**ECL**	S Foran
		SIOP	P A Voûte (*European Branch*)

Editor in Chief's Office:
Scientific Editor: Delphine Purves
Editorial Assistant: Sarah Hole

Elsevier Science:
Production Editors: Charmaine Alvares and Caroline Cowan

LIST OF CONTENTS

NUMBER 1

Comments and Critique

Prenatal factors may influence predisposition to breast cancer 1
R. Anbazhagan and B. A. Gusterson

Predicting the future health care expenses of cancer 3
K. Kesteloot

Papers

Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer 5
P. S. Stonelake, P. G. Baker, W. M. Gillespie, J. A. Dunn, D. Spooner, J. M. Morrison, N.J. Bundred, G. D. Oates, M. J. R. Lee, J. P. Neoptolemos, S. Y. Chan and P. R. Baker

Interferons combined with chemotherapy in the treatment of stage III–IV non-small cell lung cancer—a randomised study 11
M. Halme, P. K. Maasilta, S. O. Pyrhönen and K. V. Mattson

c-*erb*B-3 and c-*erb*B-2 protein expression in node-negative breast carcinoma—an immunocytochemical study 16
G. Gasparini, W. J. Gullick, S. Maluta, P. D. Palma, O. Caffo, E. Leonardi, P. Boracchi, F. Pozza, N. R. Lemoine and P. Bevilacqua

Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial 22
P. S. Sørensen, S. Helweg-Larsen, H. Mouridsen and H. H. Hansen

Palliation of malignant intestinal obstruction using octreotide 28
D. Khoo, E. Hall, R. Motson, J. Riley, K. Denman and J. Waxman

Second-line treatment with ifosfamide and carboplatin in patients with ovarian carcinoma relapsing after treatment with carboplatin 30
S. P. Dobbs, C. Gribbin, S. Y. Chan and E. M. Bessell

Postoperative chemotherapy increases the disease-free survival rate in primary gastric lymphomas stage IE and IIE 33
F. Pasini, A. Ambrosetti, R. Sabbioni, G. Todeschini, A. Santo, V. Meneghini, G. Perona and G. L. Cetto

Screening for anxiety and depression in cancer patients: the effects of disease and treatment 37
T. Ibbotson, P. Maguire, P. Selby, T. Priestman and L. Wallace

Non-palpable lesions of the breast detected by mammograpy—review of 1182 consecutive histologically confirmed cases 40
S. Ciatto, M. R. Del Turco, R. Bonardi, L. Cataliotti, V. Distante, G. Cardona and S. Bianchi

Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy—a phase II study of the EORTC Gynaecological Cancer Cooperative Group 45
J. P. Guastalla, J. B. Vermorken, J. A. Wils, M. George, V. Scotto, M. Nooij, W. W. ten Bokkel Huinnink, O. Dalesio and J. Renard

Is the peak in breast cancer incidence in sight? A study conducted in the southeastern Netherlands 50
H. W. Nab, P. G. H. Mulder, M. A. Crommelin, L. H.v.d. Heijden and J.-W. W. Coebergh

Dietary risk factors for cancer and adenomas of the large intestine. A case–control study within a screening trial in Denmark 53
J. Olsen, O. Kronborg, J. Lynggaard and M. Ewertz

Current and future costs of cancer 60
M. A. Koopmanschap, L. van Roijen, L. Bonneux and J. J. Barendregt

Myofibroblast and concurrent ED-B fibronectin phenotype in human stromal cells cultured from non-malignant and malignant breast tissue 66
D. Brouty-Boyé and V. Magnien

Inhibition by Shi-Quan-Da-Bu-Tang (TJ-48) of experimental hepatocarcinogenesis induced by *N*-nitrosomorpholine in Sprague–Dawley rats 74
M. Tatsuta, H. Iishi, M. Baba, A. Nakaizumi and H. Uehara

Relation of early Photofrin® uptake to photodynamically induced phototoxicity and changes of cell volume in different cell lines 78
A. Leunig, F. Staub, J. Peters, A. Heimann, C. Csapo, O. Kempski and A. E. Goetz

Epstein–Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue 84
P. Trivedi, L. F. Hu, F. Chen, B. Christensson, M. G. Masucci, G. Klein and G. Winberg

Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture 89
S. Bennis, C. Chapey, P. Couvreur and J. Robert

Simple cytokeratins in the serum of patients with lung cancer: relationship to cell death 93
N. Pendleton, N. L. Occleston, M. J. Walshaw, J. A. H. Littler, C. I. A. Jack, M. W. Myskow and J. A. Green

Isolation and *in vitro* expansion of lymphocytes infiltrating non-small cell lung carcinoma: functional and molecular characterisation for their use in adoptive immunotherapy 97
G. Melioli, G. Ratto, M. Guastella, M. Meta, R. Biassoni, C. Semino, G. Casartelli, W. Pasquetti, A. Catrullo and L. Moretta

Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases 103
U. Keilholz, C. Scheibenbogen, M. Brado, P. Georgi, D. Maclachlan, B. Brado and W. Hunstein

Feature Articles

Treatment of relapse of breast cancer after adjuvant systemic therapy—review and guidelines for future research 106
R. D. Rubens, E. Bajetta, J. Bonneterre, J. G. M. Klijn, P. E. Lønning and R. Paridaens

Measurement and valuation of quality of life in economic appraisal of cancer treatment 111
C. A. Uyl-de Groot, F. F. H. Rutten and G. J. Bonsel

News—ESO Task Force Papers

Haematopoietic growth factors in clinical medicine 118
R. Henschler, W. Brugger, L. Kanz and R. Mertelsmann

Use of granulocyte growth factors in solid tumours 120
E. Diaz-Rubio and E. Adrover

Dose optimisation and dose intensification in malignant lymphoma 122
D.C. Linch

Letters

Spontaneous growth arrest of lung metastases of osteosarcoma with a 28-year follow-up 127
E. M. Noordijk, H. M. Kroon and R. O. van der Heul on behalf of the Netherlands Committee on Bone Tumours

Leuprolide and tamoxifen in the treatment of pancreatic cancer. A phase II study 128
A. Zaniboni, F. Meriggi, G. Arcangeli, A. Alghisi, C. Huscher and G. Marini

*NF*1 gene mutation and acute myelogenous leukaemia 129
T. Horiuchi, I. Watanabe, N. Hatta, M. Matsumoto, Y. Kobayashi and S. Fujita

High cell proliferation activity determined by DNA flow cytometry predicts poor prognosis after relapse in prostate cancer 129
T. Visakorpi, T. Kylmälä, H. Tainio, T. Koivula, T. Tammela and J. Isola

Single-dose and fractionated palliative radiotherapy for bone metastases 131
S. Hukku, S. Ayyagari, N. R. Datta, A. K. Arya and N. Rastogi

Intrapericardial cisplatin therapy of malignant pericardial effusions 131
W. M. Koester and M. Winkelmann

NUMBER 2

Comments and Critique

Diet in the aetiology of cancer 133
P. Boyle

Detection of bone marrow infiltration by neuroblastoma in clinical practice: how far have we come? 134
M. M. Reid

Quality assurance of surgery in clinical trials 136
I. S. Fentiman and M. R. Christiaens

Papers

Immunological response to intrathecal and systemic treatment with ganglioside antibody R-24 in patients with malignant melanoma 137
W. Dippold, H. Bernhard and K.-H. Meyer zum Büschenfelde

Diagnostic and prognostic significance of plasma endotoxin determination in febrile patients with haematological malignancies 145
M. Yoshida, T. Obayashi, H. Tamura, S. Tanaka, T. Kawai, S. Sakamoto and Y. Miura

Audit of complete axillary dissection in early breast cancer 148
J. V. Reynolds, P. Mercer, E. W. M. McDermott, S. Cross, M. Stokes, D. Murphy and N. J. O'Higgins

Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes 150
H. de Graaf, P. H. B. Willemse, E. G. E. de Vries, D. Th. Sleijfer, P. O. M. Mulder, W. T. A. van der Graaf, C. Th. Smit Sibinga, E. van der Ploeg, W. V. Dolsma and N. H. Mulder

Influence of toremifene on the endocrine regulation in breast cancer patients 154
I. Számel, I. Hindy, B. Vincze, S. Eckhardt, L. Kangas and A. Hajba

Phase II trial of oral etoposide plus cisplatin in extensive stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group study 158
J. H. Schiller, D. S. Ettinger, M. M. Larson, W. Gradishar, D. Merkel and D. H. Johnson

Tumour necrosis factor-α, interleukin-1β and interleukin-6 in patients with renal cell carcinoma 162
C. Dosquet, A. Schaetz, C. Faucher, E. Lepage, J.-L. Wautier, F. Richard and J. Cabane

Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma 167
R. Aldeghi, P. Lissoni, S. Barni, A. Ardizzoia, G. Tancini, A. Piperno, M. Pozzi, G. Ricci, A. Conti and G. J. M. Maestroni

Expression of p21 *ras* protein as a prognostic factor in papillary thyroid cancer 171
F. Basolo, A. Pinchera, L. Fugazzola, G. Fontanini, R. Elisei, C. Romei and F. Pacini

Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer 175
M. Stenmark-Askmalm, O. Stål, S. Sullivan, L. Ferraud, X.-F. Sun, J. Carstensen and B. Nordenskjöld

Genetic linkage in Muir-Torre syndrome to the same chromosomal region as cancer family syndrome 180
N. R. Hall, V. A. Murday, P. Chapman, M. A. T. Williams, J. Burn, P. J. Finan and D. T. Bishop

Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice 183
M. Treskes, E. Boven, A. A. van de Loosdrecht, J. F. A. M. Wijffels, J. Cloos, G. J. Peters, H. M. Pinedo and W. J. F. van der Vijgh

A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer 188
K. Eguchi, H. Etou, S. Miyachi, H. Morinari, K. Nakada, K. Noda, Y. Ohkuni, K. Watanabe, Y. Yamada, Y. Ohe, T. Tamura, Y. Sasaki, T. Shinkai and N. Saijo

Feature Articles

What is the place of carboplatin in paediatric oncology? 194
F. Doz and R. Pinkerton

Does improved control of tumour growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells? 201
G. Gasparini and A. L. Harris

Diet in the aetiology of cancer: a review 207
A. B. Miller, F. Berrino, M. Hill, P. Pietinen, E. Riboli and J. Wahrendorf

Invited Viewpoints

P. Skrabanek 220

A. J. McMichael 221

P. A. Baghurst 223

C. La Vecchia 224

D. Forman 225

G. G. Giles and P. Ireland 226

S. Franceschi 227

The EORTC Central Office/Data Center 229
R. Sylvester and F. Meunier

Apoptosis 232
E. Mihich and R. T. Schimke

ESO Task Force Papers

Clinical utilisation of human haematopoietic progenitors elicited in peripheral blood by recombinant human granulocyte colony-stimulating factor (rHuG-CSF) 235
M. Bregni, S. Siena, G. Bonadonna and A. M. Gianni

Growth factors in haematology: prophylactic versus interventional use 238
M. A. Boogaerts

Letters

Phase II study of vinblastine and doxorubicin in advanced renal cell carcinoma 245
A. Jekunen, J. Stengård and S. Pyrhönen

Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a 246
T. Zenone, G. Catimel, N. Barbet and M. Clavel *

Escape phenomenon after successful bromocriptine and octreotide treatment in thyroid stimulating hormone secreting pituitary adenoma residual tissue 247
G. De Rosa, A. Testa, D. Giacomini and C. Carrozza

Mitoxantrone, 5-fluorouracil and levo-leucovorin as salvage treatment in advanced breast cancer patients 248
S. Mammoliti, L. Merlini, C. Caroti and L. Gallo

Education and Training in Oncology

Smoking cessation methods: recommendations for health professionals. Advisory Group of the European School of Oncology 253
A. Hirsch, K. Slama, A. Alberisio, G. Fowler, G. Lagrue, I. Malvezzi, M. Manley, R. Molimard and P. Tonnesen

Education in cancer palliative care. Report from a consensus meeting supported by the EC "Europe Against Cancer" programme 263
F. De Conno

Education and Training in Oncology 265

NUMBER 3

Comments and Critique

Oncogenes and radiosensitivity 279
A. M. Cassoni

ECCO 7 282
D. Purves

How long have I got doctor? 283
E.J. Maher

Papers

Prediction of survival in a hospital-based continuing care unit 284
J.R. Hardy, R. Turner, M. Saunders and R. A'Hern

Phase I and pharmacological study of intra-arterial hepatic administration of pirarubicin in patients with advanced hepatic metastases 289
J.-N. Munck, P. Rougier, G.G. Chabot, L.H. Ramirez, C. Bognel, J. Lumbroso, P. Herait, D. Elias, P. Lasser and A. Gouyette

Inconsistent expression of HLA-B antigens on peripheral blood lymphocytes of stage I melanoma patients: an indicator of poor prognosis 294
N. Cascinelli, D. Rovini, M.T. Illeni and R. Bufalino

VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer 299
W.K. Evans, D.J. Stewart, F.A. Shepherd, D. Logan, G. Goss, J.A. Maroun, R. Wierzbicki, E. Warner, J. Latreille and S. Dahrouge

Subsequent primary cancers following bladder cancer 303
E. Salminen, E. Pukkala, L. Teppo and S. Pyrhönen

The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients 307
M.J. Railo, K. v. Smitten and F. Pekonen

A comparison of early effects with two dose rates in brachytherapy of cervix carcinoma in a prospective randomised trial 312
P. Lambin, A. Gerbaulet, A. Kramar, P. Scalliet, C. Haie-Meder, G. Michel, M. Prade, J. Bouzy, E.P. Malaise and D. Chassagne

Serum concentrations of cytokines in patients with Hodgkin's disease 321
J.-Y. Blay, J.-P. Farcet, A. Lavaud, D. Radoux and S. Chouaïb

5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus 325
M. Stahl, H. Wilke, H.-J. Meyer, P. Preusser, T. Berns, U. Fink, W. Achterrath, H. Knipp, A. Harstrick, M. Berger and H.-J. Schmoll

The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2 329
M.E. Gore, E. Galligioni, C.W. Keen, R. Sorio, E.M. Loriaux, H.C. Grobben and C.R. Franks

Survival and prognostic factors in patients with localised cutaneous melanoma observed between 1980 and 1991 at the Istituto Dermopatico dell'Immacolata in Rome, Italy 333
R. Corona, M. Sciò, A. Mele, G. Ferranti, S. Mostaccioli, V. Macchini, G. Sonego, L. Ferrigno, M. Fucci, J.F. Osborn and R. Cavalieri

Phase II trial of 5-fluorouracil and the natural *l* isomer of folinic acid in the treatment of advanced colorectal carcinoma 338
R. Rosso, T. Mazzei, A. Sobrero, E. Mini, G. Cartei, P. Conte, R. Labianca, F. Cartei, A. Falcone, G. Pancera, G. Barsanti, F. Di Costanzo, A. Guglielmi, E. Bolli, L. Tixi, C. Aschele, A. Ribecco and P. Periti

Obesity and cancer risk: a Danish record-linkage study 344
H. Møller, A. Mellemgaard, K. Lindvig and J.H. Olsen

Oral contraceptives and prognosis in breast cancer: effects of duration, latency, recency, age at first use and relation to parity and body mass index in young women with breast cancer 351
L. Holmberg, E. Lund, R. Bergström, H.-O. Adami and O. Meirik

Production of monoclonal antibodies recognising the peptide core of MUC2 intestinal mucin 355
L.G. Durrant, E. Jacobs and M.R. Price

Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19 363
L.T. Mantovani, S. Miotti, S. Ménard, S. Canevari, F. Raspagliesi, C. Bottini, F. Bottero and M.I. Colnaghi

C-*raf*-1 proto-oncogene expression relates to radiosensitivity rather than radioresistance 369
H.M. Warenius, P.G.W. Browning, R.A. Britten, J.A. Peacock and U.R. Rapp

Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance 376
B. Passlick, J.R. Izbicki, S. Simmel, B. Kubuschok, O. Karg, M. Habekost, O. Thetter, L. Schweiberer and K. Pantel

N-*myc* gene copy number in neuroblastoma cell lines and resistance to experimental treatment 382
A. Livingstone, R.J. Mairs, J. Russell, J. O'Donoghue, M.N. Gaze and T.E. Wheldon

Missense polymorphism (C/T224) in the human cathepsin D pro-fragment determined by polymerase chain reaction—single strand conformational polymorphism analysis and possible consequences in cancer cells 390
I. Touitou, F. Capony, J.-P. Brouillet and H. Rochefort

Phase II trial of anaxirone (TGU) in advanced colorectal cancer: an EORTC Early Clinical Trials Group (ECTG) study 394
*E.E. Holdener, M. Clavel *, C. Sessa, W. ten Bokkel Huinink, P. Siegenthaler, C. Ludwig, O. Klepp, G. Renard, G. Decoster and H.M. Pinedo*

Symptoms and signs in metastatic spinal cord compression: a study of progression from first symptom until diagnosis in 153 patients 396
S. Helweg-Larsen and P.S. Sørensen

Amonafide as first-line chemotherapy for metastatic breast cancer 398
G. Kornek, M. Raderer, D. Depisch, K. Haider, B. Fazeny, C. Dittrich and W. Scheithauer

Feature Articles

Immunomodulatory agents: the cytokines 400
R.C. Stein and A.G. Dalgleish

Systemic treatment of colorectal cancer 404
R. Herrmann

News—ESO Task Force Papers

Dose optimisation and intensification of cytotoxics in solid tumours supported by haematopoietic growth factors 410
T. Le Chevalier

Cytokines in clinical cancer treatment trials: methodological aspects 412
U. Brennscheidt and A. Lindemann

Letters

Angiosarcoma of the breast following conserving treatment for breast cancer 416
B.J. Slotman, A.H. van Hattum, S. Meyer, K.H. Njo and A.B.M.F. Karim

Let's stop worrying about pigmented skin lesions in children 417
A. Bono, C. Bartoli, S.M. Zurrida, I. Del Prato, C. Clemente and N. Cascinelli

Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days 417
T.J. O'Rourke, T.D. Brown, K. Havlin, J.G. Kuhn, J.B. Craig, H.A. Burris, W.G. Satterlee, P.G. Tarassoff and D.D. Von Hoff

Human tumour bank in Croatia: a possible model for a small bank as part of the future European tumour bank network 419
R. Spaventi, L. Pecur, K. Pavelic, Z.P. Pavelic, S. Spaventi and P.J. Stambrook

Treatment of patients with metastatic melanoma with a one day regimen of dacarbazine, vincristine, bleomycin and lomustine plus interferon-α 420
M. Vuoristo, P. Gröhn, E. Kumpulainen and M. Korpela

Bioavailability of oral etoposide in gastric cancer 420
B.G. Taal, J.H. Beijnen, F.G.M. Teller, W.W. ten Bokkel Huinink, R. Dubbelman and H. Boot

Why don't we use a "cavalieri"? 421
J. K. D. Bentzen

NUMBER 4

Comments and Critique

Can we increase survival in breast cancer with innovative applications of conventional drugs? 423
S.M. Swain and L.N. Harris

European Journal of Palliative Care 425
G. Hanks

Papers

A randomised double blind crossover study of domperidone and prochlorperazine suppositories for controlling emesis in outpatients receiving chemotherapy 426
I.N. Olver, C.R. Laidlaw, J.P. Matthews, J.F. Bishop, A.-M. Hayes, M. Wolf and G.C. Toner

Factors associated with bacteraemia in febrile, granulocytopenic cancer patients 430
C. Viscoli, P. Bruzzi, E. Castagnola, L. Boni, T. Calandra, H. Gaya, F. Meunier, R. Feld, S. Zinner, J. Klastersky, M. Glauser and the International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC)

The results of modified use of chemotherapy for patients with metastatic breast cancer 438
V. Hug, J. Clark and D. Johnston

Steroid hormone profile in postmenopausal women with ovarian cancer 442
M.E.R. O'Brien, M. Dowsett, I. Fryatt and E. Wiltshaw

Serum progesterone at the time of surgery and survival in women with premenopausal operable breast cancer 445
R.A. Badwe, D.Y. Wang, W.M. Gregory, I.S. Fentiman, M.A. Chaudary, P. Smith, M.A. Richards and R.D. Rubens

Tumour kinetics, response to chemotherapy and survival in primary ovarian cancer 449
A. Alama, S. Chiara, F. Merlo, N. Ragni, P.F. Conte, R. Meazza, G. Reggiardo, I. Ferrari and R. Rosso

Appraisal of a model for prediction of prognosis in advanced colorectal cancer 453
W. Graf, R. Bergström, L. Påhlman and B. Glimelius

The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma 457
C.A. Uyl-de Groot, G.J. Ossenkoppele, A.A.P.M. van Riet and F.F.H. Rutten

Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer 460
P. Pacini, E. Tucci, R. Algeri, M. Rinaldini, A. Guarnieri, S. Valzelli and B. Neri

The costs of managing severe cancer pain and potential savings from transdermal administration 463
K. Bloor, B. Leese and A. Maynard

Case–control studies of cancer in Illinois farmers using data from the Illinois State Cancer Registry and the U.S. Census of Agriculture 469
J.E. Keller and H.L. Howe

Death of a husband or marital divorce related to risk of breast cancer in middle-aged women. A nested case–control study among Norwegian women born 1935–1954 473
A. Kvikstad, L.J. Vatten, S. Tretli and S. Kvinnsland

Cancer mortality among Polish migrants to Australia 478
J. Tyczyński, W. Tarkowski, D.M. Parkin and W. Zatoński

MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression 484
R.E. Hall, S.N. Birrell, W.D. Tilley and R.L. Sutherland

Growth inhibition of xenotransplanted human carcinomas by a monoclonal antibody directed against the epidermal growth factor receptor 491
H.-G. Schnürch, M. Stegmüller, A. Vering, M.W. Beckmann and H.G. Bender

Acidic and basic fibroblast growth factors in human breast tissue 496
J. Smith, A. Yelland, R. Baillie and R.C. Coombes

Identification of p53 mutations by means of single strand conformation polymorphism analysis in gynaecological tumours: comparison with the results of immunohistochemistry 504
J. Schneider, M.P. Rubio, F.J. Rodriguez-Escudero, B.R. Seizinger and J.S. Castresana

Inhibition of calcium-dependent protein kinase C by hexadecylphosphocholine and 1-*O*-octadecyl-2-*O*-methyl-rac-glycero-3-phosphocholine do not correlate with inhibition of proliferation of HL60 and K562 cell lines 509
D. Berkovic, K. Berkovic, E.A.M. Fleer, H. Eibl and C. Unger

Synergistic antiproliferative activity of suramin and α2A-interferon against human colorectal adenocarcinoma cell lines: *in vitro* studies 516
A. Falcone, R. Danesi, L. Zaccaro, D. Pieracci, E. Pfanner, C. Cianci, M. Andreuccetti, G. Malvaldi, M. Del Tacca and P.F. Conte

Modulation of cisplatin cytotoxicity by human recombinant interferon-γ in human ovarian cancer cell lines 520
A. Nehme, A.M. Julia, S. Jozan, C. Chevreau, R. Bugat and P. Canal

H7, an inhibitor of protein kinase C, inhibits tumour cell division in mice bearing ascitic Ehrlich's carcinoma 525
V. Felipo, M.-D. Miñana, H. Cabedo, F. Perez-Minguez, A. Llombart-Bosch and S. Grisolía

Mutation analysis of *RASK* and the 'FLR exon' of *NF1* in sporadic ovarian carcinoma 528
W.D. Foulkes, P. Englefield and I.G. Campbell

A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-α in the treatment of advanced renal cell carcinoma or melanoma 530
M. Vuoristo, I. Jantunen, S. Pyrhönen, T. Muhonen and P. Kellokumpu-Lehtinen

Feature Articles

Oncogene transgenic mice as therapeutic models in cancer research 533
H. Thomas and F.R. Balkwill

ESO Advisory Reports

Management of non-palpable and small lesions found in mass breast screening 538
M. Tubiana, R. Holland, D.B. Kopans, J.M. Kurtz, J.Y. Petit, F. Rilke, V. Sacchini and S. Tornberg

Sun exposure, UVA lamps and risk of skin cancer 549

News

Overviews and mega-trials: two new initiatives in colorectal cancer 561
R. Gray

Letters

Monoarthritis of the ankle: an unusual presentation of metastatic breast carcinoma 563
S. Menon, C.R. Smith and M. Baum

Four patients with recurrences of Hodgkin's disease after 15 years or more 565
C. Schaake-Koning, P. van Heerde, A. Hensen and R. Somers

Phase II study of tauromustine in disseminated malignant melanoma 566
S.B. Gjedde, H.T. Mouridsen, E. L-Madsen, N.V. Jensen, E. Blomquist, J. Bergh, M. Söderberg and S. Wählby

The relevance of drug DNA sequence specificity to anti-tumour activity 567
S. Neidle, M.S. Puvvada and D.E. Thurston

Lack of prognostic value of flow cytometric DNA content analysis in colorectal adenocarcinomas 569
S. Sciallero, L. Bonelli, E. Geido, L. Lettieri, E. Zeraschi, P. Bruzzi, H. Aste and W. Giaretti

Subcutaneous sacrococcygeal myxopapillary ependymoma. A case report 570
G. Botti, A. Gravina, F. Cremona, F. Izzo, M. Rigutini and A. Picone

Correction 571

NUMBER 5

Comments and Critique

PML/RARα + ATRA = CR. A comment on acute promyelocytic leukaemia: molecular pathology and treatment 573
M.J.S. Dyer

Serum neurone-specific enolase and other neuroendocrine markers in lung cancer 574
J.A. Ledermann

Radiosensitivity testing of normal tissues: a way to optimise radiotherapy? 576
P. Lambin and P. Lawton

Adjuvant treatment of colon cancer. A plea for a large-scale European trial 578
J. Wils, H. Bleiberg and Ph. Rougier

Adjuvant treatment of colon cancer 579
I. Taylor

Papers

Serum p53 auto-antibodies: incidence in familial breast cancer 580
J.A. Green, B. Mudenda, J. Jenkins, S.J. Leinster, M. Tarunina, B. Green and L. Robertson

Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain 584
M. Rodríguez, C. Barutell, M. Rull, R. Gálvez, J. Pallarés, F. Vidal, L. Aliaga, J. Moreno, J. Puerta and P. Ortiz

Cisplatin–fotemustine combination in inoperable non-small cell lung cancer: preliminary report of a French multicentre phase II trial 587
A. Rivière, A. Le Cesne, J. Berille, S. Baio and T. Le Chevalier

Management of breast cancer in the elderly 590
L.M. Martin, C. le Pechoux, E. Calitchi, Y. Otmezguine, F. Feuilhade, B. Brun, P. Piedbois, J.J. Mazeron, M. Julien and J.P. le Bourgeois

Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group 596
E. Bajetta, M. Di Bartolomeo, F. de Braud, F. Bozzetti, A.M. Bochicchio, P. Comella, D. Fagnani, G. Farina, C. Ferroni, R. Franchi, V. Gebbia, G. Ianniello, A. Tirillo, G. Pinotti, G. Schieppati, G. Ucci, M. Visini, A. Zaniboni, R. Buzzoni, C. Casartelli and P. Nelli

CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation 601
D. Rastel, A. Ramaioli, F. Cornillie and B. Thirion on behalf of the CYFRA 21-1 Multicentre Study Group

A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer 606
L. Del Mastro, O. Garrone, M.R. Sertoli, G. Canavese, A. Catturich, M. Guenzi, R. Rosso and M. Venturini

Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting 610
H. Anderson, N. Thatcher, A. Howell, K. Logan, T. Sage and K.M. de Bruijn

Intrinsic radiosensitivity of adult and cord blood lymphocytes as determined by the micronucleus assay 615
D.N. Floyd and A.M. Cassoni

Primary chemotherapy and delayed surgery for non-metastatic telangiectatic osteosarcoma of the extremities. Results in 28 patients 620
G. Bacci, P. Picci, S. Ferrari, L. Sangiorgi, A. Zanone and A. Brach del Prever

The importance of dose scheduling with mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer 626
J. Jolivet, K. Bélanger, L. Yelle, R. Guévin, M. Potvin, J. Wilson, L. Rudinskas, J. Latreille, J. Dionne, L. Gagné and J. Ayoub

Efficacy and tolerability of tropisetron in comparison with a combination of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin-containing chemotherapy 629
B. Sorbe, T. Högberg, A. Himmelmann, M. Schmidt, I. Räisänen, M. Stockmeyer and K. M. de Bruijn

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials 635
B. Bergman, N.K. Aaronson, S. Ahmedzai, S. Kaasa and M. Sullivan for the EORTC Study Group on Quality of Life

Is there potential for granulocyte or granulocyte–macrophage colony stimulating factors in radiotherapy? 642
P. Janssens, C. Mitine, M. Beauduin and P. Scalliet

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6 645
S.M. Scholl, A. Fourquet, B. Asselain, J.Y. Pierga, J.R. Vilcoq, J.C. Durand, T. Dorval, T. Palangié, M. Jouve, P. Beuzeboc, E. Garcio-Giralt, R.J. Salmon, A. de la Rochefordière, F. Campana and P. Pouillart

Correlation of expression of binding sites for synthetic blood group A-, B- and H-trisaccharides and for sarcolectin with survival of patients with bronchial carcinoma 653
K. Kayser, N.V. Bovin, E.Y. Korchagina, C. Zeilinger, F.-Y. Zeng and H.-J. Gabius

Colour Doppler demonstrates venous flow abnormalities in breast cancer patients with chronic arm swelling 657
W.E. Svensson, P.S. Mortimer, E. Tohno and D.O. Cosgrove

Increased arterial inflow demonstrated by Doppler ultrasound in arm swelling following breast cancer treatment 661
W.E. Svensson, P.S. Mortimer, E. Tohno and D.O. Cosgrove

Loss of heterozygosity of tumour suppressor gene loci in human colorectal carcinoma 664
B. Iacopetta, S. DiGrandi, B. Dix, C. Haig, R. Soong and A. House

A small GTP-binding protein is frequently overexpressed in peripheral blood mononuclear cells from patients with solid tumours 670
S. Culine, N. Honore, V. Closson, J.-P. Droz, J.-M. Extra, M. Marty, A. Tavitian and B. Olofsson

Oestrogen-regulated genes in breast cancer: association of pLIV1 with lymph node involvement 675
D.L. Manning, J.F.R. Robertson, I.O. Ellis, C.W. Elston, R.A. McClelland, J.M.W. Gee, R.J. Jones, C.D. Green, P. Cannon, R.W. Blamey and R.I. Nicholson

Suramin inhibits growth and transforming growth factor-β1 (TGF-β1) binding in osteosarcoma cell lines 678
P. Kloen, C.L. Jennings, M.C. Gebhardt, D.S. Springfield and H.J. Mankin

Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens *in vitro* and in a xenograft model 682
S.P. Langdon, A.J. Crew, A.A. Ritchie, M. Muir, A. Wakeling, J.F. Smyth and W.R. Miller

Paclitaxel-induced cytotoxicity—the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein 687
M.-L. Fjällskog, L. Frii and J. Bergh

Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts 691
M.I. Nicoletti, V. Lucchini, M. D'Incalci and R. Giavazzi

Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma 697
C.H.N. Veenhof, M.E.L. van der Burg, M. Nooy, J.G. Aalders, S. Pecorelli, C.F. Oliveira, N. Rotmensz and J.B. Vermorken

Feature Articles

Cancer mapping: why not use absolute scales? 699
N. Becker

Pharmacokinetics and cancer chemotherapy 706
P. Workman and M.A. Graham

European School of Oncology. First Euro-American forum on lung cancer treatment 710
P.A. Bunn Jr., N. Van Zandwijk, U. Pastorino, J. Aisner, P. Alberto, R. Arriagada, D. Carney, R. Cornis, C. Dittrich, U. Gatzemeier, R. Ginsberg, F.A. Greco, H.H. Hansen, P. Harper, R. Henriksson, H. Huber, P. Klener, T. LeChevalier, R. Lewensohn, N. Murray, N. Niederle, P. Postmus, R. Rosell, G. Scagliotti, J.P. Sculier, T. Splinter, R. Stahel, M. Symann, N. Thatcher, M. Tonato and A. Turrisi

News 714

Letters

Long-term results of a randomised trial comparing regimens of cyclophosphamide and fluorouracil with either mitoxantrone or doxorubicin in patients with advanced breast cancer 715
P. Pouillart, J.Y. Follézou, T. Palangie, F. Feuilhade, C. George and E. Richards

Detection of platinum–DNA adducts in cord blood lymphocytes following *in utero* platinum exposure 716
O.N. Koc, M. McFee, E. Reed and S.L. Gerson

Suramin therapy for malignant thymoma: a case report 718
R. V. La Rocca, M. R. Cooper, R. Danesi, C. A. Stein and C. E. Myers

Effect of overall time and dose on the response of glottic carcinoma of the larynx to radiotherapy 719
J. F. Fowler and R. Chappell

Magnetic resonance signal alterations of the brain in asymptomatic patients treated with high-dose cisplatin for ovarian carcinoma 721
J. M. Pumar, L. Arrojo, C. Seoane, R. Garcia, J. A. Castiñeira and J. Vidal

The use of carboplatin in malignant germ cell tumours 721
C. Bokemeyer, A. Harstrick and H. -J. Schmoll

Dose intensification in the treatment of patients with testicular germ cell tumours 723
S.M. O'Reilly, D. B. Smith, E. S. Newlands and G. J. S. Rustin

The concomitant expression of oncogenes and growth factors in human breast cancer 723
R. Spaventi, K. Pavelic, Z.P. Pavelic and J.L. Gluckman

NUMBER 6

Comments and Critique

The molecular basis of cisplatin sensitivity/resistance 725
L. R. Kelland

Chemoprevention of second primary tumours: a model for intervention trials 727
S. E. Benner, S. M. Lippman and W. K. Hong

Interlaboratory comparison of oestrogen receptor data 730
S.M. Thorpe

Papers

Results of external beam radiotherapy in differentiated thyroid carcinoma: a retrospective study from the Royal Marsden Hospital 733
M.E.A. O'Connell, R.P. A'Hern and C.L. Harmer

Determination of oestrogen receptors by enzyme immunoassay. Technical differences between laboratories and their consequences 740
S. Romain, J.L. Formento, O. Guirou, M. Francoual, G. Milano and P.M. Martin

Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy 746
A.N. Wilson, A. Davis, R.S. Bell, B. O'Sullivan, C. Catton, F. Madadi, R. Kandel and V.L. Fornasier

The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study 751
T. Taube, T. Kylmälä, C. Lamberg-Allardt, T.L.J. Tammela and I. Elomaa

Blood transfusion has no effect on colorectal cancer survival. A population-based study 759
I. Garau, E. Benito, F.X. Bosch, J. Bargay, A. Obrador, J. Santamaria, J.L. Antich, J. Besalduch, J. Rifà and S. Teuchmann

Clinical prediction of survival is more accurate than the Karnofsky performance status in estimating life span of terminally ill cancer patients 764
M. Maltoni, O. Nanni, S. Derni, M. P. Innocenti, L. Fabbri, N. Riva, R. Maltoni and D. Amadori

Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study 767
M. Bolla, R. Lefur, J. Ton Van, C. Domenge, J.M. Badet, Y. Koskas and A. Laplanche

Sensitisation of human ovarian carcinoma cells to *cis*-diamminedichloroplatinum (II) by amphotericin B *in vitro* and *in vivo* 773
M. Kojima, F. Kikkawa, H. Oguchi, K. Mizuno, O. Maeda, K. Tamakoshi, H. Ishikawa, M. Kawai, N. Suganuma and Y. Tomoda

A cross-national investigation of diet and bladder cancer 778
J.R. Hebert and D.R. Miller

Cancer survival and the duration of symptoms. An analysis of possible forms of the risk function 785
A. Maguire, M. Porta, N. Malats, M. Gallén, J.L. Piñol and E. Fernandez for the ISDS II Project Investigators

Prognostic significance of pS2 protein expression in pulmonary adenocarcinoma 792
M. Higashiyama, O. Doi, K. Kodama, H. Yokouchi, H. Inaji, S. Nakamori and R. Tateishi

A randomised trial of vindesine plus interferon-α2b compared with interferon-α2b or vindesine alone in the treatment of advanced malignant melanoma 797
D. A. Vorobiof and W. R. Bezwoda

Cancer incidence in Hiroshima and Nagasaki, Japan, 1958–1987 801
M.T. Goodman, K. Mabuchi, M. Morita, M. Soda, S. Ochikubo, T. Fukuhara, T. Ikeda and M. Terasaki

p53 gene mutations in women with breast cancer and a previous history of benign breast disease 808
A. Seth, D. Palli, J.M. Mariano, R. Metcalf, M.C. Venanzoni, S. Bianchi, S.D. Kottaridis and T.S. Papas

Expression of epitopes of the tumour-associated glycoprotein 72 and clinicopathological correlations in mammary carcinomas 813
A. Contegiacomo, M. Alimandi, R. Muraro, C. Pizzi, R. Calderopoli, L. De Marchis, A. Sgambato, G. Pettinato, G. Petrella, M.R. De Filippo and R. Mariani-Costantini

Increased bone marrow toxicity of doxorubicin bound to nanoparticles 820
S. Gibaud, J. P. Andreux, C. Weingarten, M. Renard and P. Couvreur

EWS/FLI-1 rearrangement in small round cell sarcomas of bone and soft tissue detected by reverse transcriptase polymerase chain reaction amplification 827
A. Pellin, J. Boix, J.R. Blesa, R. Noguera, C. Carda and A. Llombart-Bosch

Deficient repair of cisplatin–DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients 832
B.T. Hill, K.J. Scanlon, J. Hansson, A. Harstrick, M. Pera, A.M.J. Fichtinger-Schepman and S.A. Shellard

The use of non-clonogenic assays in measuring the response of cells *in vitro* to ionising radiation 838
P. Price and T.J. McMillan

Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study 842
J. Verweij, I. Judson, W. Steward, R. Coleman, P. Woll, C. van Pottelsberghe, M. van Glabbeke and H. Mouridsen

Feature Articles

Individual dose adaptation of anticancer drugs 844
B. Desoize and J. Robert

The molecular control of haemopoiesis and leukaemia 852
L. Sachs

News: A Workshop Report

Cancer screening in the European Union 860
A. del Moral Aldaz, M. Aupee, S. Batal-Steil, S. Cecchini, J. Chamberlain, S. Ciatto, N.A. Elizaga, B. Gairard, G. Grazzini, C. Guldenfels, B. Herity, P.A. Kosmidis, E. Lynge, E. Paci, R. Renaud, B.P. Robra, V.L. Rodrigues, H. Sancho-Garnier, P. Schaffer, D.P. da Silva, M. Tubiana, M.R. del Turco, W.A. van Veen and A. Vandenbroucke

Cervical cancer screening. Human benefits and human costs in the evaluation of screening programmes 873
N. Segnan

Breast cancer screening: methods, human benefits, human costs 875
F. de Waard and H. Mouridsen

Colorectal cancer screening: methods, benefits and costs 877
O. Kronborg and J. Wahrendorf

Economics of cancer screening: total costs and benefits in economic terms 879
K.M. Pedersen

To screen or not to screen. How do we decide on which cancer screening activities to embark upon? 884
J.D.F. Habbema and G.J. van Oortmarssen

Letters

Determination of oestrogen receptors by enzyme immunoassay 888
R.A. Weigand, D. Lynch and D. Cotter

Acute pain syndrome at tumour site in neoplastic patients treated with vinorelbine: report of unusual toxicity 889
V. Gebbia, A. Testa, R. Valenza, G. Cannata, F. Verderame and N. Gebbia

Weekly therapy with folinic acid and high-dose 5-fluorouracil 24-hour infusion in previously untreated patients with metastatic colorectal carcinoma 890
H.J. Weh, J. Dierlamm and D.K. Hossfeld

Phase II study of 4-epirubicin, etoposide and cisplatin as neoadjuvant chemotherapy in locally advanced breast cancer 891
M. A. Costa, J. E. Lamarca and G. R. Bader

Heterogeneous interaction of interferon-β and taxol in human ovarian cancer cells *in vitro* 892
S. Sen, A. Zocchetti, P. Beccaglia, G. Balconi, E. Erba and M. D'Incalci

Poems syndrome with high interleukin (IL)6 and IL1β serum levels, in a patient with thyroid carcinoma and melanoma 893
E. Tartour, D. Adams, J.-F. Besancenot, W.H. Fridman and M. Schlumberger

Use of erythropoietin in the management of the haemolytic uraemic syndrome induced by mitomycin C/tamoxifen 894
M.E.R. O'Brien, S. Casey, J. Treleaven and T.J. Powles

Correction 896

NUMBER 7

Comments and Critique

Is informed consent essential for all chemotherapy studies? 897
J.S. Tobias and J. Houghton

Aggressive superficial bladder cancer 899
S.J. Harland

Breast conservative surgery: towards more personalised treatments 900
A. Costa and A. Filiberti

Papers

Haematological toxicity of radiotherapy following high-dose chemotherapy and autologous bone marrow transplantation in patients with recurrent Hodgkin's disease 903
A. Price, D. Cunningham, A. Horwich and M. Brada

Informed consent in European multicentre randomised clinical trials — are patients really informed? 907
C.J. Williams and M. Zwitter

Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study 911
S. Tumolo, B. Ramanath Rao, M. E. van der Burg, J.P. Guastalla, J. Renard and J.B. Vermorken

Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients 914
P.F.A. Mulders, W.J. Hoekstra, R.P.M. Heybroek, E.R.F.M. Schapers, A.L.M. Verbeek, G.O.N. Oosterhof, F.M.J. Debruyne and members of the Dutch South Eastern Bladder Cancer Study Group

Multimodal treatment of locally advanced transitional cell bladder carcinoma in elderly patients 918
*A. Veronesi, G. Lo Re, A. Carbone, M.G. Trovò, V. Dal Bo *, R. Talamini, S. Santarossa, M. Francini and S. Monfardini*

Prognostic factors in inflammatory breast cancer and therapeutic implications 921
T. Palangie, V. Mosseri, J. Mihura, F. Campana, P. Beuzeboc, T. Dorval, E. Garcia-Giralt, M. Jouve, S. Scholl, B. Asselain and P. Pouillart

Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck 928
E. Colella, M. Merlano, F. Blengio, F. Angelini, G.P. Ausili Cefaro, F. Scasso, V. Lo Russo, S. Cirulli, D. Giannarelli and F. Cognetti

Prognosis of breast cancer in males: an analysis of 170 cases 930
B. Salvadori, R. Saccozzi, A. Manzari, S. Andreola, R.A. Conti, F. Cusumano and M. Grassi

Clinical significance of cathepsin D in primary ovarian cancer 935
G. Scambia, P.B. Panici, G. Ferrandina, G. Salerno, G. D'Agostino, M. Distefano, R. De Vincenzo, A. Ercoli and S. Mancuso

Low-dose γ-interferon therapy is ineffective in renal cell carcinoma patients with large tumour burden 940
W.E. Aulitzky, J. Lerche, A. Thews, I. Lüttichau, N. Jacobi, M. Herold, W. Aulitzky, C. Peschel, M. Stöckle, F. Steinbach and C. Huber

Carboplatin and α-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer. A pilot study 946
G. Frasci, A. Tortoriello, G. Facchini, S. Conforti, G. Persico, P. Mastrantonio, A. Cardone and R.V. Iaffaioli

A phase I–II study of *N*-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer 950
D.I. Jodrell, W. Oster, D.J. Kerr, P.A. Canney, H. Yosef, W.P. Steward, S.B. Kaye and J. Cassidy

Immunotherapy of metastatic melanoma with interferon-α and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions 955
U. Keilholz, C. Scheibenbogen, E. Stoelben, H.D. Saeger and W. Hunstein

Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer 959
T. Tominaga, O. Abe, A. Ohshima, H. Hayasaka, J. Uchino, R. Abe, K. Enomoto, M. Izuo, H. Watanabe, O. Takatani, M. Yoshida, K. Sakai, H. Koyama, T. Hattori, T. Senoo, Y. Monden and Y. Nomura

Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer 965
G. Fountzilas, D. Skarlos, T. Giannakakis, A. Athanasiades, D. Bafaloukos, A. Kalogera-Fountzila, C. Bamia, N. Pavlidis and P. Kosmidis

Dual effect of parity on breast cancer risk 969
C. Hsieh, M. Pavia, M. Lambe, S.-J. Lan, G.A. Colditz, A. Ekbom, H.-O. Adami, D. Trichopoulos and W.C. Willett

Cancer registration in Madras Metropolitan Tumour Registry, India 974
V. Shanta, C.K. Gajalakshmi, R. Swaminathan, K. Ravichandran and L. Vasanthi

Estimating the incidence of cancers in Switzerland: 1983–1987 978
L. Raymond, J.L. Bulliard, F. Levi, F. Enderlin, A. Méan, G. Schüler and J. Torhorst

MDM2 gene amplification in human breast cancer 982
B. Quesnel, C. Preudhomme, J. Fournier, P. Fenaux and J.-P. Peyrat

Evidence against involvement of APC mutation in papillary thyroid carcinoma 984
L. Curtis, A.H. Wyllie, J.J. Shaw, G.T. Williams, A. Radulescu, C. DeMicco, D.R.F. Haugen, J.E. Varhaug, J.R. Lillehaug and D. Wynford-Thomas

Selective activation of *ras* oncogenes in follicular and undifferentiated thyroid carcinomas 987
G. Manenti, S. Pilotti, F.C. Re, G. Della Porta and M.A. Pierotti

Hypersomy of chromosome 15 with retrovirally rearranged c-*myc*, loss of germline c-*myc* and IgK/c-*myc* juxtaposition in a macrophage–monocytic tumour line 994
S. Imreh, Y. Wang, C.K. Panda, M. Babonits, H. Axelson, S. Silva, A. Szeles, F. Wiener and G. Klein

Expression of P-glycoprotein and *in vitro* or *in vivo* resistance to doxorubicin and cisplatin in breast and ovarian cancers 1002
S. Veneroni, N. Zaffaroni, M.G. Daidone, E. Benini, R. Villa and R. Silvestrini

Prognostic value of a breast cancer-associated glycoprotein detected by monoclonal antibody LU-BCRU-G7 1007
P.D. Rye and R.A. Walker

Factors affecting sensitivity to EO9 in rodent and human tumour cells *in vitro*: DT-diaphorase activity and hypoxia 1013
N. Robertson, A. Haigh, G.E. Adams and I.J. Stratford

Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine 1019
L.C. Pronk, A.S.Th. Planting, R. Oosterom, T.E. Drogendijk, G. Stoter and J. Verweij

In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of human haematological and solid tumours 1022
R. Larsson, H. Fridborg, J. Liliemark, K. Csoka, J. Kristensen, M. de la Torre and P. Nygren

A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma 1027
P.A. Philip, J. Carmichael, K. Tonkin, T.A. Ganesan and A.L. Harris

Feature Article

Cancer vaccines 1029
A.G. Dalgleish

BookReview:

Pathology of the breast by F.A. Tavassoli 1036
R.R. Millis

News:

Obituary: Federico Spreafico 1038
S. Garattini

Letters:

Vasectomy and testicular cancer 1039
K.P. Dieckmann

Unusual clonal evolution during blast crisis of chronic myeloid leukaemia (CML) 1040
F. Christodoulidou, R.T. Silver, M.J. Macera and R.S. Verma

5-HT_3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—a randomised study 1041
J. Bonneterre and B. Hecquet

5-HT_3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—a randomised study 1041
I. Jantunen and T. Muhonen

CA50 as a serum marker for pancreatic carcinoma: comparison with CA19-9 1042
C. Pasquali, C. Sperti, A. Alfano D'Andrea, V. Costantino, C. Filipponi and S. Pedrazzoli

Epirubicin plus a calmodulin inhibitor (trifluoperazine) activity in advanced pancreatic adenocarcinoma 1043
A. Abad, B. Masuti, C. Camps, A. Font, C. Balañá, J.M. Vincent, J.J. Sánchez and members of the T.T.D. Cooperative Spanish Group

A phase II study of piritrexim in patients with advanced squamous cell carcinoma of the head and neck 1044
M. Degardin, C. Domenge, P. Cappelaere, B. Luboinski, M.S. Navarrete, J.E. Scott and J.-L. Lefebvre

Prognostic significance of Epstein-Barr virus association in Hodgkin's disease 1045
A.A. Armstrong, A. Lennard, F.E. Alexander, B. Angus, S.J. Proctor, D.E.Onions and R.F. Jarrett

NUMBER 8

Comments and Critique

Gene therapy for cancer 1047
M.E. Gore and M.K. Collins

Hepatoblastoma - a bit of a success story? 1050
E.A. Shafford and J. Pritchard

Papers

Clinico-pathological criteria with prognostic relevance in hepatoblastoma 1052
D. von Schweinitz, P. Wischmeyer, I. Leuschner, D. Schmidt, Ch. Wittekind, D. Harms and H. Mildenberger

Activity of docetaxel (Taxotere) in small cell lung cancer 1058
J.F. Smyth, I.E. Smith, C. Sessa, P. Schoffski, J. Wanders, H. Franklin and S.B. Kaye on behalf of the Early Clinical Trials Group of the EORTC

Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC early clinical trials group 1061
S. Aamdal, I. Wolff, S. Kaplan, R. Paridaens, J. Kerger, J. Schachter, J. Wanders, H.R. Franklin and J. Verweij

Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC early clinical trials group 1064
U. Bruntsch, B. Heinrich, S.B. Kaye, P.H.M. de Mulder, A. van Oosterom, R. Paridaens, J.B. Vermorken, J. Wanders, H. Franklin, M. Bayssas and J. Verweij

Neurological and cognitive impairment in long-term survivors of small cell lung cancer 1067
A. Cull, A. Gregor, P. Hopwood, F. Macbeth, H. Karnicka-Mlodkowska, N. Thatcher, P. Burt, R. Stout, K. Stepniewska and M. Stewart

Paclitaxel (Taxol) induces cumulative mild neurotoxicity 1074
J.M.A. van Gerven, J.W.B. Moll, M.J. van den Bent, M. Bontenbal, M.E.L. van der Burg, J. Verweij and Ch. J. Vecht

Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2 1078
B. Escudier, F. Farace, E. Angevin, F. Charpentier, G. Nitenberg, F. Triebel and T. Hercend

A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference 1083
A. Noble, K. Bremer, L. Goedhals, D. Cupissol and S.G. Dilly on behalf of the Granisetron Study Group

Immunoscintigraphy using ^{111}In-labelled F(AB')$_2$ fragments of anti-carcinoembryonic antigen (CEA) monoclonal antibody for staging of non-small cell lung carcinoma 1089
J.-P. Vuillez, D. Moro, E. Brambilla, P.-Y. Brichon, G. Ferretti, J.C. Saccavini and C. Brambilla

Total rectal resection and colo-anal anastomosis for low rectal tumours: comparative results in a group of young and old patients 1092
E. Leo, R.A. Audisio, F. Belli, M. Vitellaro, M.T. Baldini, L. Mascheroni, R. Patuzzo, G. Rigillo, G. Rebuffoni, A. Filiberti, P. Navarria and S. Andreola

Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas 1096
F.A. van den Brûle, A. Berchuck, R.C. Bast, Fu-Tong Liu, C. Gillet, M.E. Sobel and V. Castronovo

Are breast tumours innervated? Immunohistological investigations using antibodies against the neuronal marker protein gene product 9.5 (PGP 9.5) in benign and malignant breast lesions 1100
B.S. Mitchell, U. Schumacher, V.V. Stauber and E. Kaiserling

Induction of tumour cell lysis by a bispecific antibody recognising epidermal growth factor receptor (EGFR) and CD3 1103
A. Knuth, H. Bernhard, E. Jäger, T. Wölfel, J. Karbach, C. Jäggle, W. Strittmatter and K.-H. Meyer zum Büschenfelde

Serological and immunohistochemical detection of a 65-kDa oncofetal protein in breast cancer 1108
M. Mirowski, J. Klijanienko, S. Wang, P. Vielh, Z. Walaszek and M. Hanausek

c-*myc* mRNA overexpression is associated with lymph node metastasis in colorectal cancer 1113
K. Sato, M. Miyahara, T. Saito and M. Kobayashi

Influence of dexniguldipine-HCl on rhodamine-123 accumulation in a multidrug-resistant leukaemia cell line: comparison with other chemosensitisers 1117
R. Boer, S. Haas and A. Schödl

DNA amplifications on chromosomes 7, 9 and 12 in glioblastoma detected by reverse chromosome painting 1124
U. Fischer, B. Wullich, H.P. Sattler, E. Göttert, K.D. Zang and E. Meese

Cancer registration: a feasibility study in northern Italy 1128
S. Rodella, C. Picoco, F. Stanzial, M. Turazza, L. Fiore Donati and the Collaborative Group of Pathologists for Cancer Registration in Verona

Bladder cancer incidence and survival in the south-eastern part of the Netherlands, 1975–1989 1134
L.A.L.M. Kiemeney, J.W.W. Coebergh, N.P. Koper, L.H. van der Heijden, R.P.E. Pauwels, R.F.M. Schapers and A.L.M. Verbeek

Feature Article

Inhibiting intracellular signalling as a strategy for cancer chemoprevention 1138
G. Powis and D.S. Alberts

ESO Advisory Report

Continuing medical education in oncology within the European Union 1145
J.P. Armand, P. Alberto, A.Costa, J. Estape, R.V.H. Jones, J. Overgaard and C.D. Sherman Jr

ESO Task Force Report

New approaches in cancer pharmacology: drug design and development (part 2) 1148
P. Workman, M. D'Incalci, W. Bursch, K.R. Harrap, R.E. Hawkins, S. Neidle and G. Powis

ESO Task Force Papers on Gene Therapy

Antisense therapy for malignant disease 1160
S.G. O'Brien, M.A. Kirkland and J.M. Goldman

Replicating vectors for gene therapy of cancer: risks, limitations and prospects 1165
S.J. Russell

Gene marking after bone marrow transplantation 1171
M.K. Brenner, D.R. Rill, H.E. Heslop, C.M. Rooney, W.M. Roberts, C. Li, T. Nilson and R.A. Krance

Cancer escape from immune surveillance: how can it be overcome by gene transfer? 1176
C. Bruyns, C. Gérard and T. Velu

Increasing tumour immunogenicity by genetic modification 1182
T. Blankenstein

Clinical application of immunostimulatory gene transfer 1187
B. Gansbacher

In situ delivery of suicide genes for cancer treatment 1190
R.M. Blaese, H. Ishii-Morita, C. Mullen, J Ramsey, Z. Ram, E. Oldfield and K. Culver

Regulation of gene therapy in Europe: a current statement including reference to US regulation 1193
O. Cohen-Haguenauer

News: 1201

Book Review:

Cancer surveys - Volume 18: Breast cancer 1203
J. Taylor-Papadimitriou and I.S. Fentiman

Letters:

Combination chemotherapy with carboplatin and etoposide of brain metastases from cancer 1204
A. Santini, P. Malacarne, M. Indelli and A. Maestri

Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma 1205
J.S. Morgan, M. Adams and M.D. Mason

Phase II study of mitomycin C plus 5-fluorouracil in patients with refractory ovarian cancer 1206
I. Peláez, R. López, I. Palacio, Y. Fernández, E. Estrada, E. Esteban, J.M. Buesa and A.J. Lacave

Serological and molecular study on the HLA phenotype of female breast cancer patients 1207
C. Casoli, P. Zanelli, A. Adorni, B.R. Starcich and T. Neri

False negative testicular biopsy in an extragonadal germ cell tumour 1208
P. Albers, R. Moll and G.E. Voges

Vitiligo-like lesions following immunotherapy with IFNα and IL-2 in melanoma patients 1209
C. Scheibenbogen, W. Hunstein and U. Keilholz

NUMBER 9

Comments and Critique

Aggressive non-Hodgkin's lymphoma in elderly patients: where to go from here? 1213
R. Obrist

Renal cell cancer: is there long-term survival advantage from cytokine treatment? 1214
R.T.D. Oliver

We still need common criteria for the assessment of nausea and vomiting 1217
J. Herrstedt

Papers

The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-β1 in metastatic human breast cancer: an immunocytochemical study 1218
P.A. Murray, J. Gomm, D. Ricketts, T. Powles and R.C. Coombes

The roles of patient and observer assessments in anti-emetic trials 1223
I.N. Olver, J.P. Matthews, J.F. Bishop and R.A. Smith

A phase I/II study of the intralesional injection of ricin–monoclonal antibody conjugates in patients with hepatic metastases 1227
J.R. Zalcberg, G. Pietersz, B. Toohey, J. Laird, R. Huggins, A.S. Zimet, O. Hennessy, A. McKenzie and I.F.C. McKenzie

Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections 1231
E.W. Steyerberg, H.J. Keizer, G. Stoter and J.D.F. Habbema

Long-term results of two VAB-like regimens (vinblastine + actinomycin-D + bleomycin + cyclophosphamide + cisplatin) in malignant germ cell tumours of the ovary 1239
S. Culine, C. Lhomme, J. Kattan, P. Duvillard, G. Michel and J.-P. Droz

Medical therapy of malignant nerve pain. A randomised double-blind explanatory trial with naproxen versus slow-release morphine 1244
P.L.I. Dellemijn, H.B.C. Verbiest, J.J. van Vliet, P.J. Roos and C.J. Vecht

Treatment of advanced colorectal cancer with folinic acid and 5-fluorouracil in combination with cisplatinum 1250
P. Sagaster, R. Essl, G. Teich, E. Fritz, M. Wasilewski, H. Umek, E. Dünser, H. Mascher and M. Micksche

Sex hormone levels in postmenopausal women with advanced metastatic breast cancer treated with CGS 169 49A 1254
B. Svenstrup, J. Herrstedt, N. Brünner, P. Bennett, H. Wachmann and P. Dombernowsky

Serum levels of tumour necrosis factor-α in patients with B-cell chronic lymphocytic leukaemia 1259
F. Adami, A. Guarini, M. Pini, F. Siviero, R. Sancetta, M. Massaia, L. Trentin, R. Foà and G. Semenzato

Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis 1263
Ph. Rougier, M. Ducreux, M. Mahjoubi, J.P. Pignon, S. Bellefqih, J. Oliveira, C. Bognel, Ph. Lasser, M. Ychou, D. Elias, E. Cvitkovic, J.P. Armand and J.P. Droz

Neoadjuvant chemotherapy in locally advanced gastric carcinoma—a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum 1269
Ph. Rougier, M. Mahjoubi, Ph. Lasser, M. Ducreux, J. Oliveira, M. Ychou, J.P. Pignon, D. Elias, S. Bellefqih, C. Bognel, A. Lusinchi, E. Cvitkovic and J.-P. Droz

Alteration of coagulation and fibrinolysis systems after multidrug anticancer therapy for lung cancer 1276
E. C. Gabazza, O. Taguchi, T. Yamakami, M. Machishi, H. Ibata, S. Suzuki and T. Shima

Pharmacokinetics of folinic acid and 5-methyltetrahydrofolic metabolite after repeated oral administration of calcium folinate following methotrexate treatment 1281
N. Tubiana-Mathieu, S. Monjanel-Mouterde, C. Lejeune, B. Payet, J. Catalin, Y. Carcassone and J. Cano

Phase II trial of high-dose epirubicin and cyclophosphamide in advanced breast cancer 1285
A.F. Scinto, M.C. Cercato, C. Botti, R. Tonachella, V. Ferraresi, S. Del Bianco, I. Sacchi and F. Cognetti

Serum erythropoietin levels in patients with solid tumours 1289
C. Kettelhack, D. Schöter, D. Matthias and P.M. Schlag

Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous α-interferon 1292
C. Besana, A. Borri, E. Bucci, G. Citterio, G. Di Lucca, C. Fortis, P. Matteucci, S. Tognella, M. Tresoldi, C. Baiocchi, G. Landonio, E. Ghislandi and C. Rugarli

Delayed diagnosis and large size of breast cancer after a false negative mammogram 1299
H. Joensuu, R. Asola, K. Holli, E. Kumpulainen, V. Nikkanen and L.-M. Parvinen

Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer 1302
B. Casslén, T. Bossmar, I. Lecander and B. Åstedt

Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-α 1310
S.D. Fossâ, A. Kramar and J.-P. Droz

O^6-Alkylguanine-DNA alkyltransferase activity in schistosomiasis-associated human bladder cancer 1314
A.F. Badawi, D.P. Cooper, M.H. Mostafa, T. Aboul-Azm, R. Barnard, G.P. Margison and P.J. O'Connor

Treatment of unresectable hepatocellular carcinoma with a combination of human recombinant α-2b interferon and doxorubicin: results of a pilot study 1319
J.P. Lotz, J.D. Grange, L. Hannoun, F. Boudghene, X. Amiot, D. Lamarque, T. Andre, A. Esteso, A. Bellaiche, C. Bouleuc, F. Bodin, R. Parc, J.M. Bigot and V. Izrael

The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress 1326
R.K. Portenoy, H.T. Thaler, A.B. Kornblith, J. McCarthy Lepore, H. Friedlander-Klar, E. Kiyasu, K. Sobel, N. Coyle, N. Kemeny, L. Norton and H. Scher

Non-Hodgkin's lymphoma in elderly patients: a phase II study of MCOP chemotherapy in patients aged 70 years or over with intermediate- or high-grade histology 1337
E.M. Bessell, A. Coutts, J. Fletcher, P.J. Toghill, A.J. Moloney, I.O. Ellis, G. Hulman and D. Jenkins

Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer 1342
J.P. Sculier, M. Paesmans, P. Libert, G. Bureau, G. Dabouis, J. Thiriaux, J. Michel, O. Van Cutsem, J. Schmerber, V. Giner, M.C. Berchier, R. Sergysels, P. Mommen and J. Klastersky for the European Lung Cancer Working Party

Timing of surgery influences survival in receptor-negative as well as receptor-positive breast cancer 1348
Z. Saad, M. Vincent, V. Bramwell, L. Stitt, J. Duff, M. Girotti, T. Jory, G. Heathcote, I. Turnbull and B. Garcia

Evidence for a growth effect of epidermal growth factor on MDA-MB-231 breast cancer cells 1352
N. Veber, G. Prévost, P. Planchon and A. Starzec

A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes 1360
P.R. Twentyman, T. Rhodes and S. Rayner

Radiosensitivity of new and established human melanoma cell lines: comparison of [^{3}H]thymidine incorporation and soft agar clonogenic assays 1370
E.S. Marshall, J.H.L. Matthews, J.H.F. Shaw, J. Nixon, P. Tumewu, G.J. Finlay, K.M. Holdaway and B.C. Baguley

Measurement of radiation survival using the MTT assay 1376
A. Slavotinek, T.J. McMillan and C.M. Steel

Feature Article

The genetics of familial breast cancer and their practical implications 1383
R.A. Eeles, M.R. Stratton, D.E. Goldgar and D.F. Easton

News:

European Pancreatic Cancer Reference Library System, EPCRLS 1391
T.M. Gress, F. Müller-Pillasch, G. Adler, G. Zehetner and H. Lehrach

Forthcoming events 1395

Letters:

The prognostic value of cell proliferation in non-small cell lung cancer assessed with tritiated thymidine and anti-PCNA antibodies 1397
L. Matturri, A.M. Lavezzi, F. Grignani, G. Salomoni and G.C. Roviaro

Sialyl-TN expression in gastric carcinoma 1398
F. Carneiro, L. David and M. Sobrinho-Simões

An erythropoietin-producing endometrium carcinoma 1399
J. Asin, H.P. Muller and R. Fijnheer

Adhesion to type V collagen and cloning efficiency in agar of 8701-BC breast cancer cells 1400
C. Luparello

Intracranial germ cell tumours presenting with hypopituitarism. Successful treatment with chemotherapy alone 1401
J.A. Bridgewater, R.L. Souhami, J. Allgrove, B. Kendall and J. Pritchard

Epirubicin, cisplatin and intermittent continuous infusion of 5-fluorouracil in advanced gastric cancer: an effective regimen? 1404
R.L. Poorter, P.J.M. Bakker, C.W. Taat, J.F.W. Bartelsman and C.H.N. Veenhof

Non-AIDS-related Kaposi's sarcoma in Florence, Italy (1985–1989) 1405
A. Barchielli, E. Buiatti and M. Geddes

NUMBER 10

Comments and Critique

In vitro growth behaviour of acute myeloid leukaemic cells 1407
E. Vellenga

Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase 1408
G.J. Peters, C.L. van der Wilt and C.J. van Groeningen

Lonidamine: *in vitro*/*in vivo* correlations 1411
B.A. Teicher

Papers

Consistency of histopathological reporting of breast lesions detected by screening: findings of the U.K. national external quality assessment (EQA) scheme 1414
U.K. National Coordinating Group for Breast Screening Pathology
J.P. Sloane, R. Ellman, T.J. Anderson, C.L. Brown, J. Coyne, N.S. Dallimore, J.D. Davies, D. Eakins, I.O. Ellis, C.W. Elston, S. Humphreys, D. Lawrence, J. Lowe, J. O'D. McGee, R.R. Millis, J. Nottingham, N. Ryley, D.J. Scott, J.M. Sloan, J. Theaker, P.A. Trott, C.A. Wells and H.D. Zakhour

Elevated doses of carmustine and mitomycin C, with lonidamine enhancement and autologous bone marrow transplantation in the treatment of advanced colorectal cancer: results from a pilot study 1420
F. Franchi, P. Seminara, G. Codacci Pisanelli, V. Pagani Guazzugli Bonaiuti, F. Giovagnorio and G. Gualdi

A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer 1424
G. Buccheri and D. Ferrigno for the Cuneo Lung Cancer Study Group (CuLCaSG)

Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer 1432
A. Gadducci, I. Brunetti, M.P. Muttini, A. Fanucchi, F. Dargenio, P.G. Giannessi and P.F. Conte

Safety, tolerability, efficacy and plasma concentrations of tropisetron after administration at five dose levels to children receiving cancer chemotherapy 1436
A. Suarez, E.R. Stettler, E. Rey, G. Pons, C. Simonetta-Chateauneuf, K.M. de Bruijn, G. Olive and J. Lemerle

How relevant is secondary leukaemia for initial treatment selection in Hodgkin's disease? 1441
C.F. Hess, R.D. Kortmann, H. Schmidberger and M. Bamberg

Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer 1448
R.A.E.M. Tollenaar, G.J. Liefers, O.J. Repelaer van Driel and C.J.H. van de Velde

Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer 1453
M. Dowsett, D. Smithers, J. Moore, P.F. Trunet, R.C. Coombes, T.J. Powles, R. Rubens and I.E. Smith

Limb-sparing therapy of extremity soft tissue sarcomas: treatment outcome and long-term functional results 1459
R.B. Keus, E.J.Th Rutgers, G.H. Ho, E. Gortzak, C.E. Albus-Lutter and A.A.M. Hart

Multiple defects of T helper cell function in newly diagnosed patients with Hodgkin's disease 1464
M. Clerici, E. Ferrario, D. Trabattoni, S. Viviani, V. Bonfanti, D. J. Venzon, E. Clerici, G.M. Shearer and M.L. Villa

A randomised study of cisplatin versus thiotepa as induction chemotherapy in advanced ovarian carcinoma 1470
A. Dørum, G.B. Kristensen and C. Tropé

Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study 1474
A. Veronesi, G. Cartei, D. Crivellari, M.D. Magri, M. Della Valentina, S. Foladore, M.G. Trovò, O. Nascimben, A. Sibau, R. Talamini and S. Monfardini

Metastatic medulloblastoma: the experience of the French cooperative M7 group 1478
E. Bouffet, J.C. Gentet, F. Doz, P. Tron, H. Roche, D. Plantaz, A. Thyss, J.-L. Stephan, C. Lasset, C. Carrie, C. Alapetite, M. Choux, C. Mottolese, A. Visot, J.M. Zücker, M. Brunat-Mentigny and J.L. Bernard

Immunoscintigraphy of bone sarcomas—results in 5 patients 1484
Ø.S. Bruland, Ø. Fodstad, M. Aas, Ø.P. Solheim, J. Høie, A. Skretting, M. Winderen, T. Michaelsen and A. Pihl

Patterns and temporal trends in the incidence of malignant disease in children: I. Leukaemia and lymphoma 1490
V. Blair and J.M.Birch

Patterns and temporal trends in the incidence of malignant disease in children: II. Solid tumours of childhood 1498
V. Blair and J.M. Birch

Parallel studies of clonogenic leukaemia cells and the leukaemia cell population as a whole in acute myelogenous leukaemia 1511
H.D. Preisler, S.D. Banavali, M. Yin, G. Venu, Y.Q. Li, F. Gaskins and A. Raza

A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil 1517
A. Beck, M.C. Etienne, S. Chéradame, J.L. Fischel, P. Formento, N. Renée and G. Milano

Wide range for optimal concentration of folinic acid in fluorouracil modulation—experimental data on human tumour cell lines 1522
A. Beck, M.C. Etienne, S. Chéradame, J.L. Fischel, P. Formento, T. Guillot and G. Milano

p53 protein and vimentin in invasive ductal NOS breast carcinoma—relationship with survival and sites of metastases 1527
W. Domagala, G. Striker, A. Szadowska, A. Dukowicz, B. Harezga and M. Osborn

In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells 1534
R. Villa, N. Zaffaroni, L. Orlandi, A. Bearzatto, A. Costa and R. Silvestrini

Point mutations in the mdr1 promoter of human osteosarcomas are associated with *in vitro* responsiveness to multidrug resistance relevant drugs 1541
U. Stein, W. Walther and V. Wunderlich

The synergistic and antagonistic effects of cytotoxic and biological agents on the *in vitro* antitumour effects of suramin 1545
R. Lopez Lopez, R.E.N. van Rijswijk, J. Wagstaff, H.M. Pinedo and G.J. Peters

Intron splice acceptor site sequence variation in the hereditary non-polyposis colorectal cancer gene *hMSH2* 1550
N.R. Hall, G.R. Taylor, P.J. Finan, R.D. Kolodner, W.F. Bodmer, S.E. Cottrell, I. Frayling and D.T. Bishop

Tissue-specific expression of neural cell adhesion molecule (NCAM) may allow differential diagnosis of neuroblastoma from embryonal rhabdomyosarcoma 1552
E.G. Phimister, A. Culverwell, K. Patel and J.T. Kemshead

Oestradiol stimulates growth of oestrogen receptor-negative MDA-MB-231 breast cancer cells in immunodeficient mice by reducing cell loss 1559
A. Friedl and V.C. Jordan

A novel microculture kinetic assay (MiCK assay) for malignant cell growth and chemosensitivity 1564
V.D. Kravtsov

Feature Articles:

The S-100-related calcium-binding protein, p9Ka, and metastasis in rodent and human mammary cells 1570
R. Barraclough and P.S. Rudland

Prospects for proton-beam radiotherapy 1577
A.E. Nahum, D.P. Dearnaley and G.G. Steel

Oestrogens, proteases and breast cancer. From cell lines to clinical applications 1583
H. Rochefort

Book Review:

Cancer surveys—Volumes 19/20: Trends in cancer incidence and mortality 1587
R. Doll, C.S. Muir and J.F. Fraumeni

News:

Forthcoming events 1588

Letters:

Economic and clinical evaluation of therapy of HIV-related non-Hodgkin's lymphoma with chemotherapy and granulocyte colony-stimulating factor (G-CSF) 1589
U. Tirelli and E. Vaccher

Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide 1590
H. Scherübl, B. Wiedenmann, E.O. Riecken, F. Thomas, E. Böhme and U. Räth

Hepatitis C virus infection and B-cell lymphomas 1591
C. Ferri, F. Caracciolo, L. La Civita, M. Monti, G. Longombardo, F. Greco and A.L. Zignego

Mitoxantrone and 5-fluorouracil modulated by the pure (6S) stereoisomer of leucovorin as second-line chemotherapy for advanced breast cancer 1593
P. Pronzato, G. Bertelli, F. Vaira, A. Vigani and P. Losardo

A rapidly progressing leiomyosarcoma expressing drug-resistance markers failed to respond to cyclosporin A-associated chemotherapy 1594
S. Oudard, S. Chevillard, F. Lokiec, T. Dorval, M.F. Poupon and P. Pouillart

A pilot study of early hospital discharge in adult patients with fever and neutropenia 1595
N.J. Meropol, K.R. Fox, D.J. Vaughn and N. Zeiber

NUMBER 11

Comments and Critique

Pre-operative radiotherapy for rectal cancer: what benefit? Which technical parameters? 1597
J.-C. Horiot and J.F. Bosset

Post-mastectomy radiotherapy: is it cure after all? 1600
S. Jefferies and J. Yarnold

Papers

Long-term results of a randomised trial of short-course low-dose adjuvant pre-operative radiotherapy for rectal cancer: reduction in local treatment failure 1602
P.A. Goldberg, R.J. Nicholls, N.H. Porter, S. Love and J.E. Grimsey

Accelerated chemotherapy for poor prognosis germ cell tumours 1607
A. Horwich, D.P. Dearnaley, A. Norman, J. Nicolls and W.F. Hendry

Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-α2b and folinic acid. The "GISCAD" experience 1611
R. Labianca, G. Giaccon, S. Barni, G. Ambrosini, A. Iirillo, G. Fiorentini, M. Duro, E. Piazza, C. Oliani, G. Pancera, S. Cascinu, G. Martignoni, A. Zaniboni, G. Dallavalle and G. Luporini on behalf of GISCAD (Italian Group for the Study of Digestive Tract Cancer)

Inter-relationships between single carbon units' metabolism and resting energy expenditure in weight-losing patients with small cell lung cancer. Effects of methionine supply and chemotherapy 1616
H. Sengeløv, O.P. Hansen, L. Simonsen, J. Bülow, O.J. Nielsen and L. Ovesen

Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer 1621
L.A.L.M. Kiemeney, J.A. Witjes, R.P. Heijbroek, F.M.J. Debruyne and A.L.M. Verbeek

Management of bowel obstruction in patients with advanced ovarian cancer 1625
F.A.N. Zoetmulder, Th. J.M. Helmerhorst, F. v. Coevorden, P.E. Wolfs, J.P.H. Leyer and A.A.M. Hart

Testosterone levels as a marker of prognosis to goserelin treatment in metastatic breast cancer 1629
G. Secreto, P. Boracchi, R. Buzzoni, E. Venturelli, A. Cavalleri and S. Dolci

Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation 1631
C.A. Uyl-de Groot, D.J. Richel and F.F.H. Rutten

Local recurrences of soft tissue sarcomas in adults: a retrospective analysis of prognostic factors in 102 cases after surgery and radiation therapy 1636
S. Dinges, V. Budach, W. Budach, H.J. Feldmann, M. Stuschke and H. Sack

Sudden tumour regression with enhanced natural killer cell accumulation in a patient with stage IV breast cancer 1642
A.G. Maiche, A. Jekunen, P. Rissanen, P. Virkkunen, J. Halavaara and J.P. Turunen

At what age do sunburn episodes play a crucial role for the development of malignant melanoma 1647
J. Westerdahl, H. Olsson and C. Ingvar

Immunohistochemical localisation of hydroxysteroid sulphotransferase in human breast carcinoma tissue: a preliminary study 1654
S. Sharp, J.M. Anderson and M.W.H. Coughtrie

Estimating completeness of cancer registration in Saarland/Germany with capture–recapture methods 1659
H. Brenner, C. Stegmaier and H. Ziegler

Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen 1663
S.R.D. Johnston, K.A. MacLennan, N.P.M. Sacks, J. Salter, I.E. Smith and M. Dowsett

In vitro sequence-dependent synergistic effect of suramin and camptothecin 1670
R. Lopez, G.J. Peters, E. Smitskamp-Wilms, J.A. Virizuela, J. van Ark-Otte, H.M. Pinedo and G. Giaccone

Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells 1675
M.C. Pagliacci, M. Smacchia, G. Migliorati, F. Grignani, C. Riccardi and I. Nicoletti

Somatostatin receptor expression in lung cancer 1682
K.J. O'Byrne, G. Halmos, J. Pinski, K. Groot, K. Szepeshazi, A.V. Schally and D.N. Carney

Effects of the microtubule-disturbing agents docetaxel (Taxotere®), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines *in vitro* 1688
A.-R. Hanauske, H. Depenbrock, D. Shirvani and J. Rastetter

Relationships between tamoxifen binding proteins in primary breast cancer biopsies 1694
S. Marsigliante, G. Leo, M. D'Elia, G.P. Vinson, S. Greco, J. Puddefoot and C. Storelli

P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance 1701
E. Sheridan, P. Silcocks, J. Smith, B. W. Hancock and M. H. Goyns

Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by *in situ* hybridisation 1705
G.A. Thomas, M.A. Barrand, S. Stewart, P.H. Rabbitts, E.D. Williams and P.R. Twentyman

Mutational analysis of the first 14 exons of the Adenomatous Polyposis Coli (APC) gene 1709
Z. Dobbie, M. Spycher, R. Hürliman, R. Ammann, T. Ammann, J. Roth, A. Müller, Hj. Müller and R.J. Scott

Feature Articles:

Should clinicians be concerned about the carcinogenic potential of tamoxifen? 1714
V.C. Jordan and M. Morrow

Control of oncogene expression by antisense nucleic acids 1721
C. Hélène

News:

Forthcoming events 1727

Letters:

Salivary glands enlargement in association with cytosine arabinoside application in patients with acute myeloid leukaemia 1727
P. Cetkovský and V. Koza

Low-dose BCG in superficial bladder cancer with strain Connaught Canada—as effective as strain Pasteur Paris? 1728
D. Mack and J. Frick

Human leucocyte interferon-α therapy can induce a second response in treatment of thrombocytosis in patients with neutralising antibodies to recombinant interferon-α2a 1729
M. Merup, E. Törnebohm-Roche, K. Engman and C. Paul

Recombinant interferon-γ in a patient with multiple myeloma 1731
A. Palumbo, B. Bruno, S. Triolo, M. Boccadoro and A. Pileri

L-*myc* allele polymorphism and prognosis for metastases in Russian gastric cancer patients 1732
N.M. Mironov, A.-M. Aguelon, G.I. Potapova, O.V. Gorbunov, A.A. Klimenkov and H. Yamasaki

Male breast cancer: incidence, mortality and survival rates from an Italian population-based series 1732
E. Crocetti and E. Buiatti

FLEP (5-fluorouracil, leucovorin, etoposide, cisplatin) in advanced gastric cancer 1733
M. González-Barón, J. Feliu, E. Espinosa, C. García-Girón, I. Chacon, P. Garrido and A. Colmenarejo

Escalating doses of mitoxantrone with granulocyte colony-stimulating factor (G-CSF) rescue plus 5-fluorouracil and high-dose levofolinic acid in metastatic breast cancer 1734
V. Gebbia, R. Valenza, A. Testa, G. Cannata, F. Verderame and N. Gebbia

NUMBER 12

Announcement

Genetics of cancer—special issue 1737
I.R. Hart

Comments and Critique

BRCA1, BRCA2, BRCA3 . . . A myriad of breast cancer genes 1738
D.T. Bishop

Second-line chemotherapy in epithelial ovarian carcinoma: platinum again? Taxanes? How to choose? 1739
J.P. Guastalla

Papers

Local injection of OK-432/fibrinogen gel into head and neck carcinomas 1741
H. Kumazawa, T. Yamashita, T. Tachikawa, M. Minamino and Y. Nakata

One-year follow-up of the 'Starting Again' group rehabilitation programme for cancer patients 1744
G. Berglund, C. Bolund, U.-L. Gustafsson and P.-O. Sjödén

A classification after radical cystectomy of patients with bladder cancer associated with schistosomiasis 1751
M. Rafla, A.S. Ibrahim, A.J. Valleron and J.Y. Mary

High dose level radiation therapy for local tumour control in esthesioneuroblastoma 1757
F. Guedea, E. Van Limbergen and W. Van Den Bogaert

Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis 1760
M.B. Møller, F. d'Amore and B.E. Christensen on behalf of the Danish Lymphoma Study Group, LYFO

Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen 1764
G. Bolis, G. Scarfone, L. Luchini, C. Ferraris, F. Zanaboni, M. Presti, G. Giardina, A. Villa and F. Parazzini

Clinical evaluation of serum tissue polypeptide-specific antigen (TPS) in non-small cell lung cancer 1768
J.-L. Pujol, E.H. Cooper, J. Grenier, D.A. Purves, M. Lehmann, P. Ray, M.D. Aouta, M. Bashir, P. Godard and F.B. Michel

Weekly doxorubicin with or without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer. A randomised study 1775
S. Gundersen, E. Hannisdal, S. Lundgren and E. Wist for the Norwegian Breast Cancer Group

Adult Wilms' tumour: review of 22 cases 1778
J. Kattan, M.-F. Tournade, S. Culine, M.-J. Terrier-Lacombe and J.-P. Droz

Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancer 1783
A. van der Gaast, C.H.H. Schoenmakers, T.C. Kok, B.G. Blijenberg, W.C.J. Hop and T.A.W. Splinter

In vivo cell kinetic measurements in human oesophageal cancer: what can be learned from multiple biopsies? 1787
K. Haustermans, L. Vanuytsel, K. Geboes, T. Lerut, J. Van Thillo, J. Leysen, W. Coosemans and E. van der Schueren

Medullary carcinoma of the breast, prognostic importance of characteristic histopathological features evaluated in a multivariate Cox analysis 1792
L. Pedersen, S. Holck, T. Schiødt, K. Zedeler and H.T. Mouridsen

Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma 1797
S. Vesalainen, P. Lipponen, M. Talja and K. Syrjänen

The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2 1804
J.G.M. Scharenberg, A.G.M. Stam, B.M.E. von Blomberg, G.J. Roest, P.A. Palmer, C.R. Franks, C.J.L.M. Meijer and R.J. Scheper

Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy 1809
B. Rajan, G. Ross, C.C. Lim, S. Ashley, D. Goode, D. Traish and M. Brada

DNA content as a predictor of clinical outcome in soft tissue sarcoma patients 1815
W. Budach, V. Budach, B. Socha, M. Stuschke, C. Streffer and H.Sack

Identification of potassium flux pathways and their role in the cytotoxicity of estramustine in human malignant glioma, prostatic carcinoma and pulmonary carcinoma cell lines 1822
P.-E. Sandström, Ö. Jonsson, K. Grankvist and R. Henriksson

Stable analogues of the antitumour agent trimelamol retain *in vitro* cytotoxicity in drug-sensitive and resistant rodent and human cell lines 1827
H.M. Coley, M. Jarman, N. Brooks, T.J. Thornton and I.R. Judson

Viscum album L. extracts reduce sister chromatid exchanges in cultured peripheral blood mononuclear cells 1836
A. Büssing, T. Azhari, H. Ostendorp, A. Lehnert and K. Schweizer

Targeting of tumours with murine and reshaped human monoclonal antibodies against placental alkaline phosphatase: immunolocalisation, pharmacokinetics and immune response 1842
H.P. Kalofonos, C. Kosmas, V. Hird, D.E. Snook and A.A. Epenetos

Urinary excretion of growth factors in patients with ovarian cancer 1851
M. Feldkämper, U. Enderle-Schmitt, R. Hackenberg and K.-D. Schulz

Interferon alpha and 5'-deoxy-5-fluorouridine in colon cancer: effects as single agents and in combination on growth of xenograft tumours 1859
P.L. Laurent, H.T. Tevaearai, J.F. Eliason, J.-C. Givel and N. Odartchenko

Soluble intercellular adhesion molecule-1 (ICAM-1) is released into the serum and ascites of human ovarian carcinoma patients and in nude mice bearing tumour xenografts 1865
R. Giavazzi, M.I. Nicoletti, R.G.S. Chirivi, I. Hemingway, S. Bernasconi, P. Allavena and A.J.H. Gearing

Autolymphocyte therapy—I. *In vivo* tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using *ex vivo* activated memory T-lymphocytes 1871
J.E. Gold and M.E. Osband

Prognostic significance of pS2 mRNA in breast cancer 1882
S.J. Wysocki, B.J. Iacopetta and D.M. Ingram

Feature Articles:

Cancer and the heat shock response 1884
K.J. Fuller, R.D. Issels, D.O. Slosman, J.-G. Guillet, T. Soussi and B.S. Polla

Peri-operative hormones and prognosis in breast cancer 1892
I.S. Fentiman and W.M. Gregory

News:

Third meeting of the DCIS Working Party of the EORTC (Fondazione Cini, Isola S. Giorgio, Venezia, 28 February 1994)—conference report 1895
A. Recht, J.A. van Dongen, I.S. Fentiman, R. Holland and J.L. Peterse

Letters:

Tropisetron (Navoban®) compared with alizapride in the control of emesis induced by cyclophosphamide-containing regimens 1902
A. De Nigris, G. Paladini, F. Giosa, C. Sfeir, M.G. Pagan and C. Maltoni

The treatment of progressive ovarian carcinoma with D-Trp-LHRH (decapeptyl) 1903
F. Carnino, L. Iskra, G. Fuda, G. Foglia, F. Odicino, M. Bruzzone, S. Chiara, A. Gadducci and N. Ragni for the Gruppo Oncologico Nord ovest (GONO)

Acute morphine intoxication during high-dose recombinant interleukin-2 treatment for metastatic renal cell cancer 1905
R. Bortolussi, F. Fabiani, F. Savron, V. Testa, R. Lazzarini, R. Sorio, F. De Conno and A. Caraceni

Prognostic impact of DNA content and a classification system for ploidy (AUER classification) in primary fallopian tube carcinoma (FTC) 1907
A.C. Rosen, A.H. Graf, G.W. Hacker and M. Klein

Phase II study of 4′epirubicin in advanced squamous cell oesophageal cancer 1908
M. Spielmann, D. Gandia, K. Fizazi, T. Guillot, E. Cvitkovic, L. Kayitalire, T. Girinsky, D. Elias, P. Rougier and J. Kac

Pilot study of high dose fenretinide and vitamin A supplementation in bladder cancer 1909
A. Decensi, S. Bruno, R. Torrisi, S. Parodi and A. Polizzi

Correction 1910

NUMBER 13

Papers

Introduction 1911
N.R. Lemoine and H.C. Hurst

Human nucleotide excision repair syndromes: molecular clues to unexpected intricacies 1912
J.H.J. Hoeijmakers

Genetic polymorphisms in xenobiotic metabolism 1921
C.A.D. Smith, G. Smith and C.R. Wolf

Li–Fraumeni syndrome 1935
J.M. Birch

The genetics of childhood cancer 1942
D. Malkin and C. Portwine

The genetics of colorectal cancer 1946
D.T. Bishop and N.R. Hall

The genetics of breast cancer 1957
D.M. Black

Multiple endocrine neoplasia type 1 (MEN1) 1961
J.T. Pang and R.V. Thakker

Multiple endocrine neoplasia type 2 1969
C.J. Forster-Gibson and L.M. Mulligan

Neurofibromatosis type 1 1974
S.D. Colman and M.R. Wallace

Neurofibromatosis type 2 1981
G. Thomas, P. Mérel, M. Sanson, K. Hoang-Xuan, J. Zucman, C. Desmaze, T. Melot, A. Aurias and O. Delattre

Von Hippel-Lindau disease 1987
E.R. Maher

Genetic predisposition to melanoma 1991
M.H. Skolnick, L.A. Cannon-Albright and A. Kamb

Recent advances in the genetics of metastasis 1995
H. Ponta, M. Hofmann and P. Herrlich

Genetics of growth arrest and cell death: key determinants of tissue homeostasis 2001
P.A. Hall and D.P. Lane

Genetic counselling in the cancer family clinic 2012
V. Murday

Screening for cancer predisposition 2015
A.F. Markham, P.L. Coletta, P.A. Robinson, P. Clissold, G.R. Taylor, I.M. Carr and D.M. Meredith

Pre-implantation diagnosis of inherited predisposition to cancer 2030
W.J. Gullick and A.H. Handyside

Gene replacement strategies for the prevention and therapy of cancer 2032
J.A. Roth, T. Mukhopadhyay, W.W. Zhang, T. Fujiwara and R. Georges

NUMBER 14

Comments and Critique

Clinical reversal of the multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction? 2039
H.L. McLeod

Papers

Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer 2042
M. Fernö, B. Baldetorp, Å. Borg, J.-P. Brouillet, H. Olsson, H. Rochefort, G. Sellberg, H. Sigurdsson and D. Killander for the South Sweden Breast Cancer Group

In vivo stimulation by tamoxifen of cathepsin D RNA level in breast cancer 2049
T. Maudelonde, C. Escot, P. Pujol, P. Rouanet, A. Defrenne, J.-P. Brouillet and H. Rochefort

Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma 2054
L.M. Samuel, V.J. Harvey, P.L. Mitchell, P.I. Thompson, D. Mak, P. Melville and B.D. Evans

Cytotoxic effects of long-term circulating ultrafiltrable platinum species and limited efficacy of haemodialysis in clearing them 2057
J.-L. Lagrange, E. Cassuto-Viguier, V. Barbé, J.-L. Fischel, J.-R. Mondain, M.-C. Etienne, J.-M. Ferréro, A. Creisson-Ducray, P. Formento and G. Milano

Prognostic factors for local control, regional control and survival in oropharyngeal squamous cell carcinoma 2060
C.A. Regueiro, G. Aragón, I. Millán, F.J. Valcárcel, A. de la Torre and R. Magallón

Apoptosis in breast cancer as related to histopathological characteristics and prognosis 2068
P. Lipponen, S. Aaltomaa, V.-M. Kosma and K. Syrjänen

Patient population analysis in EORTC trial 22881/10882 on the role of a booster dose in breast-conserving therapy 2073
A. Ptaszynski, W. Van den Bogaert, M. Van Glabbeke, M. Pierart, H. Bartelink, J.C. Horiot, A. Fourquet, H. Struikmans, H. Hamers, R.P. Müller, W.J. Hoogenraad, J.J. Jager and E. van der Schueren

Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease 2082
A. Berruti, M. Tampellini, M. Torta, T. Buniva, G. Gorzegno and L. Dogliotti

Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation 2085
J. Prendiville, P. Lorigan, F. Hicks, B. Leahy, R. Stout, P. Burt and N. Thatcher

Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG) 2091
A. Ohtsu, Y. Shimada, S. Yoshida, H. Saito, S. Seki, K. Morise and M. Kurihara

A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma 2093
J. Chang, H. Atkinson, R. A'Hern, A. Lorentzos and M.E. Gore

Trends in cancer mortality in young adults in Europe, 1955–1989 2096
S. Franceschi, F. Levi, F. Lucchini, E. Negri, P. Boyle and C. La Vecchia

Expression of functional very late antigen-α_1, -α_2, -α_3 and -α_6 integrins on Ewing's sarcoma and primitive peripheral neuroectodermal tumour cells and modulation by interferon-γ and tumour necrosis factor-α 2119
F. van Valen, H. Hanenberg and H. Jürgens

Constitutive secretion of bioactive transforming growth factor β_1 by small cell lung cancer cell lines 2125
J.R. Fischer, H. Darjes, H. Lahm, M. Schindel, P. Drings and P.H. Krammer

Colony-stimulating factor-producing tumours: production of granulocyte colony-stimulating factor and interleukin-6 is secondary to interleukin-1 production 2130
R. Tsuyuoka, T. Takahashi, Y. Sasaki, Y. Taniguchi, M. Fukumoto, A. Suzuki, K. Nakamura, S. Kobayashi, T. Kudo and K. Nakao

Aldehyde dehydrogenase involvement in a variant of the Brown Norway rat acute myelocytic leukaemia (BNML) that acquired cyclophosphamide resistance *in vivo* 2137
C.J. de Groot, A.C.M. Martens and A. Hagenbeek

Molecular and cellular effects of hexadecylphosphocholine (Miltefosine) in human myeloid leukaemic cell lines 2143
T. Beckers, R. Voegeli and P. Hilgard

The relative roles of vitronectin receptor, E-selectin and $\alpha_4\beta_1$ in cancer cell adhesion to interleukin-1-treated endothelial cells 2151
R.M. Lafrenie, S. Gallo, T.J. Podor, M.R. Buchanan and F.W. Orr

Expression of π-glutathione S-transferase gene (GSTP1) in gastric cancer: lack of correlation with resistance against cis-diamminedichloroplatinum (II) 2158
Y. Kodera, S. Akiyama, K. Isobe, K. Kondo, K. Ito, M. Yamauchi and H. Takagi

EORTC Receptor Study Group Report

Technical evaluation of thymidine kinase assay in cytosols from breast cancers 2163
S. Romain, F. Spyratos, O. Guirou, S. Deytieux, O. Chinot and P.M. Martin

Feature Articles

Colorectal cancer and the integrin family of cell adhesion receptors: current status and future directions 2166
M.V. Agrez and R.C. Bates

Protease inhibitors: role and potential therapeutic use in human cancer 2170
Y.A. DeClerck and S. Imren

News

Forthcoming events 2181

Letters

Interferon-α–carboplatin combination therapy for metastatic melanoma: phase II study 2182
E.M. Kokoschka, J. Klocker, U. Loicht, A. Rehberger, W. Macheiner and M. Micksche

Lymphomas associated with the endemic (African) variant of Kaposi's sarcoma: a chemosensitive but fatal entity 2183
M.E. Stein, R. Ben-Yosef, K. Drumea and D. Spencer

Thyroid-stimulating hormone (TSH) suppression in differentiated thyroid carcinoma: combined treatment with triiodothyronine and thyroxine 2184
C.L. Maini, R. Sciuto, A. Tofani, I. Rosito, G. Franciotti and L. Pisano

Prognostic significance of phagocytic functions in breast cancer patients 2185
J. Lukač, S. Lechpammer, Z. Kusić, A. Bolanča and N. Dakorić

A new model for the interaction of EGF-like ligands with their receptors: the new one-two 2186
W.J. Gullick

Treatment of interleukin-2-induced thrombocytopenia by intravenous immunoglobulin 2187
V. Cottin, S. Négrier, J.-Y. Ranchère, A. Mercatello, Y. Merrouche, C. Négrier and T. Philip

Mitoxantrone and ifosfamide as second-line therapy of epithelial ovarian cancer. A pilot study by the I.T.M.O. Group 2188
A. Di Leo, E. Bajetta, L. Biganzoli, S. Bohm, G. Lupi, S. Oriana, G. Riboldi, G. Spatti, F. Zunino and F. Di Re

Informed consent and truth in medicine 2189
A. Surbone

SUPPLEMENT 1

First Educational Convention of the European School of Oncology, Paris, Palais des Congrès, 16–18 June 1994—Abstract Book

SUPPLEMENT 2

6th EORTC Breast Cancer Working Conference, Amsterdam, RAI Congress Centre, 6–9 September 1994–Abstract Book

SUPPLEMENT 3

Introduction S1
G. Bonadonna, D. Linch and J.L. Prugnaud

Applications of recombinant DNA technology in the production of glycosylated recombinant human granulocyte colony stimulating factor S2
C.J. Holloway

Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor (lenograstim) S7
M. Ono

Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency S12
C. Nissen

Granulocyte colony stimulating factor: from laboratory bench to clinical use S15
T.M. Dexter

The optimal dose of glycosylated recombinant human granulocyte colony stimulating factor for use in clinical practice: a review S20
M. Marty

The clinical benefits of recombinant human granulocyte colony stimulating factor in the treatment of cancer patients S26
A. Bacigalupo

Chemotherapy dose intensity facilitated by use of lenograstim—implications for quality of life and survival S30
C. Gisselbrecht

The changing face of stem cell transplantation by the use of recombinant human granulocyte colony stimulating factor S34
M.A. Boogaerts and H. Demuynck

Evaluation of haematopoietic growth factors: defining relevant clinical endpoints in growth factor trials S40
D.C. Linch

Future strategy for cancer treatment using recombinant human granulocyte colony stimulating factor S44
V. Diehl